Skip to main content
An official website of the United States government
Government Funding Lapse

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

IVIG for Infection Prevention After CAR-T-Cell Therapy

Major Program
Supportive Care and Symptom Management
Sponsor
Fred Hutchinson Cancer Center
Status
Recruiting
NCT ID
NCT05952804
This phase II trial compares the effects of immunoglobulin replacement therapy with a placebo for preventing infectious complications in patients receiving CD19 chimeric antigen receptor (CAR)-T cell therapy. Hypogammaglobulinemia is a common complication in patients who receive CD19 CAR-T cell therapy. This is a condition in which the level of immunoglobulins (antibodies) in the blood is low and the risk of infection is high. Immunoglobulin replacement therapy works by replacing the body's immunoglobulin G (IgG) antibodies with donor blood product derived IgG antibodies that may help prevent infection. IgG antibodies are often depleted as a result of CAR-T therapy. Giving immunoglobulin replacement therapy may prevent infectious complications in patients receiving CD19 CAR-T cell therapy.
Intervention
Anti-CD19 CAR T Cells Preparation, Biospecimen Collection, Electronic Health Record Review, Immune Globulin Infusion (Human), 10% Solution, Saline, Survey Administration
Condition
Hematologic Malignancies
Investigators
Joshua Hill, MD, Frederick Locke, MD, Matthew Frigault, MD, Sanjeet Dadwal, MD, Miguel-Angel Perales, MD

See list of participating sites